Fiera Capital Corp cut its stake in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 563,567 shares of the company's stock after selling 19,821 shares during the period. Fiera Capital Corp owned 0.96% of Inari Medical worth $23,242,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Motley Fool Asset Management LLC boosted its holdings in Inari Medical by 46.2% in the first quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company's stock valued at $3,103,000 after acquiring an additional 20,438 shares during the last quarter. Bamco Inc. NY boosted its holdings in shares of Inari Medical by 27.4% during the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company's stock worth $37,288,000 after buying an additional 167,000 shares in the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of Inari Medical during the 2nd quarter worth approximately $2,145,000. Integral Health Asset Management LLC boosted its holdings in shares of Inari Medical by 100.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company's stock worth $19,260,000 after buying an additional 200,000 shares in the last quarter. Finally, Seven Eight Capital LP bought a new position in shares of Inari Medical during the 1st quarter worth approximately $499,000. 90.98% of the stock is currently owned by institutional investors.
Inari Medical Stock Down 0.9 %
NASDAQ NARI traded down $0.45 on Friday, reaching $51.39. The company had a trading volume of 1,072,521 shares, compared to its average volume of 974,953. The stock has a market capitalization of $3.01 billion, a P/E ratio of -38.07 and a beta of 0.96. The company's fifty day moving average is $44.43 and its 200 day moving average is $46.49. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13.
Analyst Ratings Changes
A number of equities analysts have issued reports on NARI shares. Canaccord Genuity Group increased their price target on Inari Medical from $71.00 to $74.00 and gave the stock a "buy" rating in a report on Tuesday, October 29th. Wells Fargo & Company cut their price target on Inari Medical from $84.00 to $65.00 and set an "overweight" rating on the stock in a report on Wednesday, July 31st. Robert W. Baird increased their price target on Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a report on Tuesday, October 29th. Deutsche Bank Aktiengesellschaft started coverage on Inari Medical in a report on Friday, August 9th. They set a "buy" rating and a $68.00 price target on the stock. Finally, Piper Sandler upped their target price on Inari Medical from $50.00 to $52.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Inari Medical has an average rating of "Hold" and a consensus target price of $58.89.
View Our Latest Report on Inari Medical
Insider Activity at Inari Medical
In other news, Director William Hoffman sold 40,000 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the sale, the director now directly owns 643,296 shares of the company's stock, valued at $29,482,255.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares of the company's stock, valued at $22,265,500. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William Hoffman sold 40,000 shares of the firm's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00. Following the sale, the director now directly owns 643,296 shares of the company's stock, valued at approximately $29,482,255.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 131,000 shares of company stock valued at $6,161,340. 10.60% of the stock is owned by insiders.
Inari Medical Company Profile
(
Free Report)
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
See Also
Before you consider Inari Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.
While Inari Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.